Get started
Author

Katie Wozniak

OpenAlex ID: A5022038328
Clinical response and pathway-specific correlates following TIGIT–LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial
2024 · Shambavi Richard, Alexander M. Lesokhin, et al. · Nature Cancer · 22
PDF
Abstract CT262: Durable responses following anti-TIGIT (BMS-986207) and anti-LAG3 (BMS-980616) in combination with pomalidomide in relapsed myeloma: MMRF MyCheckpoint trial
2023 · Hearn J. Cho, Shambavi Richard, et al. · Cancer Research · 4
Selinexor, Ixazomib, Pomalidomide and Dexamethasone in Functionally High-Risk Multiple Myeloma: Results from the Myeloma Developing Regimens Using Genomics (MyDRUG) Sub-Protocol Y3
2023 · Joshua Richter, Jeffrey A. Zonder, et al. · Blood · 3
Adaptive versus Fixed Designs in Confirmatory Clinical Trials: Centering the Choice on Ethics
2025 · Stef Baas, Lukas Pin, et al. · SSRN Electronic Journal · 1
Modernizing multiple myeloma clinical trial eligibility to improve equity and inclusivity by hematological parameters
2024 · Lauren Merz, Monique Hartley-Brown, et al. · Seminars in Hematology · 1
PA-286 Longitudinal Single-Cell Profiling Reveals Reproducible Clonal Expansion of Cytotoxic CD8+ TEMRA Cells Following Daratumumab-Based Therapy
2026 · Chaitanya Acharya, Reyka Jayasinghe, et al. · Clinical Lymphoma Myeloma & Leukemia
Adaptive versus fixed designs in confirmatory clinical trials: centering the choice on ethics
2026 · Stef Baas, Lukas Pin, et al. · Clinical Trials
Abstract 3887: Multiple myeloma risk classification of CoMMpass using Consensus Genomic Staging identifies differences between patients with high and low African genetic ancestry.
2026 · Steven M. Foltz, Chaitanya R. Acharya, et al. · Cancer Research
Direct-to-patient research: Opportunity brings challenges
2025 · Anne Quinn-Young, Michael Andreini, et al. · Cancer Treatment and Research Communications
Works count: 9
Citation count: 31
H-index: 3
I10-index: 1
Year
Topic
Type